Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT
Company Participants
Dr. Christopher Anzalone – Chairman, CEO & President
Conference Call Participants
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Presentation
Prakhar Agrawal
Senior Biotech Analyst
All right. Welcome, everyone. Day 2 of Cantor’s Global Healthcare Conference. My name is Prakhar Agrawal, biotech analyst at Cantor. For the next session, we have the team of Arrowhead, and representing Arrowhead, we have Chris Anzalone, President, Chairman and CEO of the company. Chris, I appreciate you taking out time.
Dr. Christopher Anzalone
Chairman, CEO & President
Thank you for having us. It’s great to be here.
Question-and-Answer Session
Prakhar Agrawal
Cantor Fitzgerald & Co., Research Division
I’m sure we have a lot to talk about in terms of some of the updates from this week, but maybe just level set expectations in terms of what you see as the key priorities for the company right now.
Dr. Christopher Anzalone
Chairman, CEO & President
Sure. We have a really busy 6 to 9 months ahead of us in essentially chronological order. I think what you’re going to see is we will bring MAPT to the clinic. That’s going to be our first CNS drug that is administered via a subcu injection. After that, I think we’ll bring our first dimer into the clinic. That’s PCSK9 APOC3 dimer that we think is a really potentially powerful tool against ASCVD.
In November, we’ve got our PDUFA date for plozasiran. That’s a huge event for us to transition from an R&D only to an R&D plus commercial company. We’ll have some INHBE and ALK7 data in obesity. I think by the end of the year, we’ll have a bit more ALK7 data in the first half of ’26. That’s about 6 months behind INHBE in dosing.
Read the full article here
